Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

NASH

Novel therapeutic strategies targeting ASK1 in NASH

Nature Reviews Gastroenterology & Hepatology volume 14, pages 329–330 (2017)Cite this article

Subjects

Currently, no pharmacological therapies are approved for the treatment of NASH. A new study now identifies CASP8 and FADD-like apoptosis regulator (CFLAR) as a novel suppressor of NASH and its associated disorders in a process dependent on the activation of apoptosis signal-regulating kinase 1 (ASK1).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mechanism of ASK1 regulation in NASH.

References

  1. Wree, A., Broderick, L., Canbay, A., Hoffman, H. M. & Feldstein, A. E. From NAFLD to NASH to cirrhosis — new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10, 627–636 (2013).

    Article  CAS  Google Scholar 

  2. Feldstein, A. E. et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437–443 (2003).

    Article  Google Scholar 

  3. Li, H. et al. Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension 56, 1109–1117 (2010).

    Article  CAS  Google Scholar 

  4. Wang, P.-X. et al. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat. Med. http://dx.doi.org/10.1038/nm.4290, (2017).

  5. Sakauchi, C., Wakatsuki, H., Ichijo, H. & Hattori, K. Pleiotropic properties of ASK1. Biochim. Biophys. Acta 1861, 3030–3038 (2017).

    Article  CAS  Google Scholar 

  6. Xiang, M. et al. Targeting hepatic TRAF1–ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. J. Hepatol. 64, 1365–1377 (2016).

    Article  CAS  Google Scholar 

  7. Xie, L. et al. DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity. J. Hepatol. 65, 113–124 (2016).

    Article  CAS  Google Scholar 

  8. Tobiume, K. et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2, 222–228 (2001).

    Article  CAS  Google Scholar 

  9. Aouadi, M., Binetruy, B., Caron, L., Le Marchand-Brustel, Y. & Bost, F. Role of MAPKs in development and differentiation: lessons from knockout mice. Biochimie 88, 1091–1098 (2006).

    Article  CAS  Google Scholar 

  10. Kawarazaki, Y., Ichijo, H. & Naguro, I. Apoptosis signal-regulating kinase 1 as a therapeutic target. Expert Opin. Ther. Targets 18, 651–664 (2014).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

S.S. is funded by the German Research Foundation (DFG; SCHU 3146/1-1). A.E.F. is supported by the US National Institutes of Health (NIH; grants R01 DK113592, U01 AA022489 and R21AA023574).

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of California, San Diego, Biomedical Research Building II, 9500 Gilman Drive, MC0602, La Jolla, 92093, California, USA

    Susanne Schuster & Ariel E. Feldstein

Authors
  1. Susanne Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ariel E. Feldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ariel E. Feldstein.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

FURTHER INFORMATION

ClinicalTrials.gov

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schuster, S., Feldstein, A. Novel therapeutic strategies targeting ASK1 in NASH. Nat Rev Gastroenterol Hepatol 14, 329–330 (2017). https://doi.org/10.1038/nrgastro.2017.42

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2017.42

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing